Emergent Biosolutions (EBS) Issues Q3 Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q3 EPS of $0.04, $0.06 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $58.8 million versus the consensus estimate of $63.59 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Emergent BioSolutions (EBS) Misses Q3 EPS by 23c
- North American Construction (NOA) Misses Q3 EPS by 27c; Offers Guidance
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
